PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

TARRYTOWN, New York, April 11, 2024– via IBN– PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials